Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Cardiology

  • News

    Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs

    October 11, 2021

    Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.

  • 1
    News

    New reports help nail down myocarditis risk with COVID-19 vaccine

    October 11, 2021

    Myocarditis linked to the two mRNA SARS-CoV-2 vaccines is rare, usually mild and self-limited, and a lot less likely than the usually more severe cases seen in COVID-19.

  • News

    Is AFib a stroke cause or innocent bystander? The debate continues

    October 5, 2021

    Many believe AFib is a risk marker for stroke, but new evidence suggests it may be a causal risk factor.

  • 1
    News

    Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs

    September 27, 2021

    SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.

  • News

    Cardiogenic shock teams again tied to lower mortality

    September 23, 2021

    New data suggest centers with a shock team had higher survival and lower resource use in the cardiac ICU.

  • 1
    News

    Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems

    September 21, 2021

    In an observational registry-based study, dropping the 110-bpm heart rate threshold improved sensitivity for low-risk PE, while increasing it improved specificity for intermediate-high–risk PE.

  • 1
    News

    EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition

    September 20, 2021

    Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say forget that.

  • 1
    News

    Top 10 things to know about the AHA ACLS 2020 updates

    September 17, 2021

    A quick summary for hospitalists of the AHA guidelines for cardiopulmonary resuscitation and emergency cardiovascular care.

  • News

    Poor lung function linked to risk for sudden cardiac death

    September 16, 2021

    Every standard deviation decrease in forced expiratory volume in 1 second (FEV1) was associated with a 23% increase in risk for sudden cardiac death.

  • News

    COVID vaccine preprint study prompts Twitter outrage

    September 16, 2021

    The authors’ conclusions about rates of myocarditis after COVID vaccine in boys aged 12-17 years are attacked for supposedly stoking antivaccine sentiment.

Previous1 … 7 8 9 10 11 … 79Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences